SCHEMBL16611606

SCHEMBL16611606

CC1(C)OCC(Cn2cc(-c3ccc(S(N)(=O)=O)cc3)c3c(=O)[nH]ccc32)O1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PLK4 O00444 1/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39
TEK Q02763 1/20 0.39
CA2 P00918 6/20 0.36
CA12 O43570 4/20 0.36
CA1 P00915 4/20 0.36
CA9 Q16790 4/20 0.36
JAK2 O60674 3/20 0.33
JAK1 P23458 3/20 0.33
KDM4E B2RXH2 2/20 0.32
HPGD P15428 2/20 0.32
HSD17B10 Q99714 2/20 0.32
TSHR P16473 1/20 0.32
BRD4 O60885 3/20 0.32
TMEM97 Q5BJF2 2/20 0.32
SIGMAR1 Q99720 2/20 0.32
IKBKB O14920 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16726660 0.87 ALDH1A1 (0.47) ALDH1A1NPSR1PLK4FLT4KDR
SCHEMBL18052596 0.86 ALDH1A1 (0.44) ALDH1A1NPSR1PLK4FLT4KDR
SCHEMBL16610896 0.80 PLK4 (0.41) ALDH1A1NPSR1PLK4FLT4KDR
SCHEMBL16611521 0.72 CA12 (0.39) ALDH1A1PLK4FLT4KDRTEK
SCHEMBL16610867 0.69 CA12 (0.38) KDRTEKCA2CA12CA1
SCHEMBL16611244 0.69 JAK2 (0.43) CA2CA12CA1CA9JAK2
SCHEMBL16610905 0.69 CA12 (0.39) TEKCA2CA12CA1CA9
SCHEMBL16610986 0.68 JAK2 (0.43) CA2CA12CA1CA9JAK2
SCHEMBL16610987 0.68 JAK2 (0.43) CA2CA12CA1CA9JAK2
SCHEMBL16610984 0.68 JAK2 (0.43) CA2CA12CA1CA9JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 ALDH1A1 3511/4885NPSR1 2927/4885PLK4 620/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 ALDH1A1 3511/4885NPSR1 2927/4885PLK4 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.